ArticlePLoS neglected tropical diseases2015
Fitness of Leishmania donovani parasites resistant to drug combinations.
Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- Global, regional, and national age-gender-specific trends, decomposition analysis, and Bayesian age-period-cohort modelling for projections of the burden of leishmaniasis: A population-based ecological study.Current research in parasitology & vector-borne diseases · 2026Article
- Optimization of Physicochemical Properties and ADME for 2,4-Substituted 1Journal of medicinal chemistry · 2025Article
- New immunomodulatory treatment protocol for canine leishmaniosis reduces parasitemia and proteinuria.PLoS neglected tropical diseases · 2024Article
- Strasseriolides display in vitro and in vivo activity against trypanosomal parasites and cause morphological and size defects in Trypanosoma cruzi.PLoS neglected tropical diseases · 2023Article
- Amphotericin B resistance correlates with increased fitnessFrontiers in microbiology · 2023Article
- Interspecies and Intrastrain Interplay amongMicroorganisms · 2022Review
- Discovery of Novel Pyruvate Kinase Inhibitors AgainstTurkish journal of pharmaceutical sciences · 2021Article
- Insights from Leishmania (Viannia) guyanensis in vitro behavior and intercellular communication.Parasites & vectors · 2021Article
- Treatment failure to sodium stibogluconate in cutaneous leishmaniasis: A challenge to infection control and disease elimination.PloS one · 2021Article
- Structure-property studies of an imidazoquinoline chemotype with antitrypanosomal activity.RSC medicinal chemistry · 2020Article
- Leishmania heme uptake involves LmFLVCRb, a novel porphyrin transporter essential for the parasite.Cellular and molecular life sciences : CMLS · 2020Article
- Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-Journal of medicinal chemistry · 2020Article
- Thiol-ene "Click" Synthesis and Pharmacological Evaluation ofMolecules (Basel, Switzerland) · 2019Article
- Molecular Basis of the Leishmanicidal Activity of the Antidepressant Sertraline as a Drug Repurposing Candidate.Antimicrobial agents and chemotherapy · 2018Article
- Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs.International journal for parasitology. Drugs and drug resistance · 2018Article
- Building protein-protein interaction networks for Leishmania species through protein structural information.BMC bioinformatics · 2018Article
- The impact of within-host ecology on the fitness of a drug-resistant parasite.Evolution, medicine, and public health · 2018Article
- Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.PLoS neglected tropical diseases · 2017Review
- Evolution of resistance to single and combined floral phytochemicals by a bumble bee parasite.Journal of evolutionary biology · 2017Article
- Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major.PLoS neglected tropical diseases · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug resistance represents one of the main problems for the use of chemotherapy to treat leishmaniasis. Additionally, it could provide some advantages to Leishmania parasites, such as a higher capacity to survive in stress conditions. In this work, in mixed populations of Leishmania donovani parasites, we have analyzed whether experimentally resistant lines to one or two combined anti-leishmanial drugs better support the stress conditions than a susceptible line expressing luciferase (Luc line). In the absence of stress, none of the Leishmania lines showed growth advantage relative to the other when mixed at a 1:1 parasite ratio. However, when promastigotes from resistant lines and the Luc line were mixed and exposed to different stresses, we observed that the resistant lines are more tolerant of different stress conditions: nutrient starvation and heat shock-pH stress. Further to this, we observed that intracellular amastigotes from resistant lines present a higher capacity to survive inside the macrophages than those of the control line. These results suggest that resistant parasites acquire an overall fitness increase and that resistance to drug combinations presents significant differences in their fitness capacity versus single-drug resistant parasites, particularly in intracellular amastigotes. These results contribute to the assessment of the possible impact of drug resistance on leishmaniasis control programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.